Engflag

Tamsil

Quick links to important sections

Tamsil

Tamsil_IS

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tamsil

Property Description
Active ingredient Terbinafine (as Hydrochloride)
Form Tablet, Cream, Solution, Spray
Pharmacological class Antifungal Agent (Allylamine)
Common use To eliminate fungal infections (Mycoses)
Origin Synthetic compound

Defining Tamsil: An Allylamine Antifungal Agent

Tamsil is a pharmaceutical preparation that belongs to the pharmacological class of antifungal agents (antimycotics). Its identity is defined by its sole active ingredient, Terbinafine, frequently utilized as Terbinafine Hydrochloride. This molecule is a synthetic compound classified as an allylamine derivative, a class that has been clinically recognized for its rapid onset of fungicidal action against susceptible fungi. Tamsil's purpose is to provide a targeted mechanism for actively eliminating the source of fungal infections, differentiating its approach from fungistatic treatments.

Composition and Forms: Systemic versus Topical Use

The drug is a single active ingredient product available in multiple distinct dosage forms, including the oral tablet for systemic antifungal treatment, and preparations like creams or solutions for topical/dermal application. This flexibility in the route of administration allows Tamsil to address both localized surface issues and more complex cases, such as nail infections, where the oral route is necessary for deep tissue penetration. The topical forms contain Terbinafine within a pharmaceutical base or vehicle formulated for dermal use.

General Purpose: Targeting Fungal Cell Disruption

Terbinafine's general therapeutic purpose is to clear fungal infections by directly compromising the structural integrity and metabolism of the fungal cell. The molecule functions as an inhibitor of squalene epoxidase, an enzyme essential for the fungal cell's synthesis of ergosterol. This selective interference leads to a fungicidal action, resolving the underlying pathology of mycoses by killing the fungal pathogen.

What side effects are possible with Tamsil?

Tamsil: Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Tamsil (Terbinafine) as documented in official government regulatory information.

Frequency-Classified Adverse Reactions

The safety profile is formally organized by the likelihood of occurrence, ranging from very common to very rare, based on clinical data and post-marketing surveillance. Very Common (ge 1/10) effects listed include headache, gastrointestinal symptoms (such as diarrhea, nausea, dyspepsia, and abdominal pain), rash, and musculoskeletal reactions (arthralgia, myalgia). Common effects (ge 1/100 to < 1/10) include dizziness. Uncommon effects (ge 1/1,000 to < 1/100) include taste disturbance (dysgeusia).

Serious Adverse Reactions and Key Constraints

Regulatory documents highlight the possibility of rare (ge 1/10,000 to < 1/1,000) but clinically significant reactions, particularly hepatic dysfunction (hepatitis, cholestasis, and, in very rare cases, liver failure). Severe dermatological reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and serious blood disorders (neutropenia, pancytopenia) are also documented.

Population-Specific Safety and Exposure Patterns

Terbinafine is contraindicated for patients with pre-existing active or chronic liver disease. The medicine is also generally not recommended for use in individuals with severely impaired renal function or during breastfeeding. Official labeling notes that sensory disturbances, specifically loss of taste or smell (anosmia), may be prolonged or, in rare instances, permanent following the discontinuation of treatment.

Overdose and Emergency Response

The official documentation describes that an acute overdose with Tamsil (terbinafine) may result primarily in gastrointestinal and central nervous system manifestations. These documented presentations include symptoms such as nausea, vomiting, epigastric pain, headache, dizziness, rash, and frequent urination. The ingestion of doses significantly above the prescribed amount, or accidental ingestion of other formulations like topical cream, constitutes an event requiring urgent professional evaluation.

Required Emergency Actions

In the event of a suspected overdose, regulators mandate immediate action. Individuals must seek immediate medical attention by contacting a Poison Control Center or an Emergency Room. For severe, life-threatening scenarios—specifically if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened—emergency services must be called at once.

Management and Treatment

The management approach is defined as symptomatic and supportive therapy, as regulatory labeling explicitly states that no specific antidote is known for Terbinafine overdose. The official procedure is to attempt to eliminate the unabsorbed drug, which includes the administration of Activated Charcoal. Although a formal severity classification is not provided, the requirement for urgent hospital evaluation dictates the need for continuous professional monitoring following an overdose event.

Therapeutic Uses of Tamsil

What Tamsil Treats: Main Uses and Benefits

Tamsil is applied in situations involving certain distressing symptoms linked to persistent fungal infections of the nails and skin. It is used in areas where short-term symptom management is appropriate, particularly when more extensive infections create significant symptomatic burden and functional strain.

This medicine is commonly used for managing conditions that present with systemic or localized discomfort, including onychomycosis (fungal nail infections), tinea corporis (ringworm of the body), tinea cruris (jock itch), and tinea pedis (athlete's foot). It is commonly used for toenail and fingernail infections, which may be less responsive to localized management.

This medication is generally considered relevant for easing the load in conditions characterized by periods of heightened, recurrent, or episodic manifestations. It helps address symptom clusters that interfere with daily comfort, such as persistent scaling, itching, and redness. The patient benefit is that it provides support that helps ease the overall symptom burden. It generally supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relevant for Symptomatic Itching

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Tamsil (Terbinafine) is strictly determined by regulatory authorities based on established safety profiles, focusing on patient age and pre-existing health conditions.

Populations Not Eligible (Contraindications)

Contraindication Affected Population
Active or Chronic Liver Disease Patients with pre-existing liver impairment.
Hypersensitivity Individuals with a history of allergic reaction to terbinafine.

Restricted or Conditional Use

Age-Related Criteria: Use is established for adults without contraindications. The safety and efficacy of the oral tablet have not been established for treating onychomycosis in children. For the elderly, no routine adjustment is necessary unless hepatic or renal impairment is present.

Comorbidity Limitations: Oral Tamsil is not recommended for patients with severe renal impairment (creatinine clearance <50 ml/min). Caution is advised for patients with pre-existing Psoriasis or Lupus Erythematosus due to the risk of exacerbation.

Physiological Status: Use of the oral tablet is not recommended during pregnancy or while breastfeeding as terbinafine is excreted into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oral Tamsil (Terbinafine) has officially documented pharmacokinetic interactions primarily related to enzyme metabolism. The medicine is a strong inhibitor of the CYP450 2D6 isozyme, a key metabolic pathway. This inhibition may result in an increase in the exposure of co-administered medicines that are substrates of CYP2D6, such as Desipramine, certain Beta-blockers, and some Type 1C Antiarrhythmics.

Conversely, Terbinafine's own clearance is altered by other enzyme modifiers. Co-administration with the inducer Rifampin is documented to increase Terbinafine clearance by 100%. The inhibitors Cimetidine and Fluconazole are documented to decrease Terbinafine clearance and significantly increase its plasma exposure, respectively.

Category Documented Interaction Pattern
Exposure Modification Increases AUC/Cmax of Desipramine (5-fold) and decreases the clearance of Caffeine (19%).
Food Restriction Oral granules must be taken with food and must not be mixed with applesauce or fruit-based foods.
Disease State Restriction Contraindicated in individuals with chronic or active liver disease.

Post-marketing reports related to Warfarin have noted changes in prothrombin times, though a causal link has not been conclusively established in regulatory documentation.

Mechanism of Action

How Tamsil Works

Tamsil (Terbinafine) is defined by a selective dual-mechanism that targets the metabolic machinery of the fungal cell, resulting in a fungicidal (cell-killing) outcome.

Specific Inhibition of Fungal Sterol Synthesis

Tamsil exerts its primary effect by acting as a specific inhibitor of the fungal enzyme Squalene Epoxidase (ERG1), a key biological target in the ergosterol biosynthesis pathway. This enzymatic blockade prevents the fungal cell from producing ergosterol, the vital sterol required for maintaining its cell membrane structure and fluidity. The molecule exhibits high selectivity for the fungal enzyme over analogous mammalian enzymes.

The Dual Mechanism of Cell Toxicity

The inhibition triggers a dual physiological cascade. Firstly, the cell membrane suffers from the lack of ergosterol. Secondly, the un-metabolized substrate, squalene, accumulates to toxic concentrations within the fungal cell. This simultaneous depletion and accumulation rapidly compromises the cell's structural integrity, causing lysis (rupture) and cell death, which is the foundational physiological change achieved by the mechanism.

Mechanistic Constraints

The effectiveness of this mechanism is dependent on the target enzyme's integrity. Biological constraints, such as point mutations in the fungal SQLE gene, can structurally alter the enzyme. The fungicidal outcome is typically observed against dermatophytes, while the effect on certain yeasts may be limited to a fungistatic (growth-inhibiting) outcome, representing a mechanism limitation.

Dosage and Administration Information

Administration Routes and Standard Dosing

Tamsil is utilized through two distinct official routes: the oral route for systemic therapy, primarily for nail infections (onychomycosis), and the topical/cutaneous route for localized dermal infections. The standard adult systemic treatment regimen is defined as a 250 mg tablet dose administered once daily. Topical forms, such as the 1% cream or spray, are applied locally, typically once or twice daily depending on the specific condition and formulation.

Frequency, Duration, and Context

The frequency of administration for the oral tablet is consistently once daily. The treatment duration is fixed based on the site of infection; oral therapy for fingernail onychomycosis is commonly set at 6 weeks, extending to 12 weeks for toenail onychomycosis. For tinea skin infections, oral use is typically limited to 2 to 4 weeks, while topical application ranges from 1 to 4 weeks. The oral tablet may be taken with or without food, providing flexibility in the daily schedule. For topical use, official instructions require the affected area to be thoroughly cleansed and dried prior to application.

Procedural Constraints

The full therapeutic outcome for oral treatment of nail infections is realized some months after treatment cessation, corresponding to the time required for healthy nail outgrowth. Furthermore, oral Tamsil is not recommended for use in patients with pre-existing hepatic impairment or those with a creatinine clearance less than or equal to 50 mL/min. Dosage for older adults typically requires no adjustment, although pediatric dosing utilizes weight-based oral granule formulations.

Recent Clinical Evidence

Summary of Research Evaluation

Focus of Clinical Studies

Studies were conducted to examine long-term symptoms in individuals receiving the drug. Research evaluated reported levels of pain and the time to resolution of acute flares. Long-term studies documented findings related to changes in disease activity, exploring their duration.

Key Findings and Efficacy Evaluation

The primary analysis involved randomized trials with control groups. Outcomes compared to placebo across multiple metrics were generally reported to show differences.

  • Symptom Management: Research evaluated the data collected regarding symptom scores in the initial six months of evaluation.
  • Disease Progression: Studies collected and analyzed data related to indicators of disease progression over a two-year period.
  • Combination Therapy: Research explored the recorded findings related to overall prognosis when the drug was administered alongside another standard treatment. The research does not offer a conclusion on treatment preference for early intervention.

Safety and Tolerability Profile

Studies collected safety data for this treatment in elderly patients and in those with pre-existing kidney conditions.

  • Drug Interactions: Research included the collection of data on co-administration with high doses of aspirin. Initial studies included the evaluation of data collected at the lowest dose.
  • Special Populations: The effects of the medication in individuals with liver disease have not been fully characterized. Evidence was collected from multiple trials over an extended observation period.
  • Adverse Events: The research documented adverse event data including common reports such as gastrointestinal discomfort and headache.

Key Studies & References Safety and Pharmacokinetic Evaluation of Tamsil in Elderly Patients and Patients with Renal Impairment (Special Populations Study)

Frequently Asked Questions (FAQ)

Common questions about Tamsil (FAQ)

Q: What kind of fungal infections is Tamsil used to treat?

A: Tamsil (Terbinafine) tablets are approved for treating certain fungal infections caused by dermatophytes. According to official indications, this primarily includes onychomycosis, which is a fungal infection of the toenails and fingernails. The medicine may also be used for severe cases of certain other skin fungal infections, such as tinea infections, where systemic treatment is required.

Q: What is the specific maximum daily dose for an adult?

A: Official regulatory documents define a standard daily dose for adults when Tamsil is used for systemic therapy. This standard dose is a specific tablet strength taken once daily, as determined by the prescribing information. Dosage information must be confirmed by the prescribing healthcare professional.

Q: Can Tamsil be used to treat infections in children?

A: According to official product information, the safety and effectiveness of the oral tablet have not been established for treating onychomycosis (nail fungus) in children. For some specific fungal infections in pediatric populations, separate weight-based dosing for oral granules may be available, but use is determined by a physician.

Q: What should I do if I miss a dose of the Tamsil tablet?

A: Instructions for a missed dose generally advise taking it as soon as it is remembered, unless it is close to the time for the next scheduled dose. If the next dose is due soon, the instructions suggest skipping the missed dose and resuming the regular schedule. Product information indicates that doses should not be doubled to compensate for a missed one.

Q: What happens if I stop taking the oral Tamsil before the full course is finished?

A: Official guidance emphasizes the importance of completing the full, prescribed course of treatment for a successful outcome. Stopping the medication too soon may lead to an incomplete fungal eradication. This action may be associated with an increased risk of the infection recurring.

Q: Is it safe to drink alcohol while taking Tamsil?

A: Regulatory documents do not provide a direct instruction regarding alcohol consumption. However, official information highlights the potential for serious hepatic dysfunction (liver problems) as a reported side effect. The medicine is contraindicated in patients with pre-existing active or chronic liver disease, which serves as an important general consideration for liver health during treatment.

How should Tamsil be stored and disposed of?

How to Store and Dispose of Tamsil?

To ensure product stability, Tamsil (Terbinafine) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted. The medicine must be kept in its original container, which should remain tightly closed, to protect the product from moisture.

Child Safety and Disposal

All official labeling mandates that Tamsil be kept out of the sight and reach of children.

For disposal, do not flush unused or expired Tamsil down the toilet or drain, as it is not on the official flush list. The preferred method for disposal is using a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (such as dirt or coffee grounds) in a sealed bag and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tamsil found in:

A-Z Index: